# Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes

Study · id `cardio:ct-nct05238012` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05238012](<https://clinicaltrials.gov/study/NCT05238012>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05238012

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 392 participants.

## Technical summary

Registry record NCT05238012. Randomized; no masking; primary purpose treatment. Start 2022-08-02 (actual); primary completion 2024-04-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 392 participants (enrolled count; ClinicalTrials.gov record NCT05238012, source copy `cardio:ctgov-nct05238012-2024-05-21`, retrieved 2026-10-26)
- Started: 2022-08-02 (actual) (ClinicalTrials.gov record NCT05238012, source copy `cardio:ctgov-nct05238012-2024-05-21`, retrieved 2026-10-26)
- Primary completion: 2024-04-02 (actual) (ClinicalTrials.gov record NCT05238012, source copy `cardio:ctgov-nct05238012-2024-05-21`, retrieved 2026-10-26)
- Completion: 2024-04-02 (actual) (ClinicalTrials.gov record NCT05238012, source copy `cardio:ctgov-nct05238012-2024-05-21`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05238012, source copy `cardio:ctgov-nct05238012-2024-05-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05238012-2024-05-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes
- Acronym: XTREME
- Condition: Metabolism Disorder, Lipid
- Condition: Metabolism Disorder, Glucose
- Intervention (Drug): Xuezhikang Capsule
- Intervention (Drug): Atorvastatin Calcium Tablets
- Lead sponsor: Heart Health Research Center
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: e50d633c0118908e4c343caa1753fa0e2cfebec581b93bebf5345be036874e3a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
